Building frontier AI to engineer better molecules
Chai Discovery is an AI drug discovery company that develops foundation models for molecular biology, enabling the prediction and design of biochemical interactions with atomic precision. The company's flagship model, Chai-1 and Chai-2, are multi-modal foundation models for predicting molecular structures and de novo antibody design. Chai-2 achieves an 85% success rate in zero-shot antibody discovery. Founded in 2024 by former OpenAI researchers, Chai has partnered with Eli Lilly for AI-driven biologics discovery and raised $130M in a Series B led by General Catalyst. The company operates as a partner-facing R&D and software organization supporting biologics discovery for biopharma customers.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2025
Aug 2025
Create a free account to see which investors have funded this company.
Create Free AccountAI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.
xAI is an AI platform for accelerating human scientific discovery.
Waymo is an autonomous driving technology company with a mission to make it safe and easy for peo...
